Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Team Grant: DM/TS - CIHR-JDRF - ß-cell and Pancreatic Islet Physiology

University of British Columbia

$1,000,000.00

Designing Stem Cell Derived Islets for Diabetes Therapy

EF 2021-22

Résumé
Diabetes is a debilitating disorder of high blood sugar that afflicts millions of Canadians. People living with type 1 diabetes lack the cells that release the hormone insulin, so multiple daily insulin injections remain the conventional way to control blood sugar levels and survive. Scientists in Edmonton made breakthroughs for the transplant of clusters of insulin-producing cells, called islets. The "Edmonton Protocol" is quick and works remarkably well, such that many islet recipients are able to reduce or even eliminate insulin injections. Unfortunately, the only source of islets for transplant is recently deceased donors and only a tiny fraction of those in need can receive them. There have been remarkable breakthroughs in unraveling the process by which islet cells develop naturally in the body. As a result, it is now possible to replicate this process in the lab with cultured stem cells, culminating in insulin producing cells. Exciting clinical trials are now underway in which islet precursor cells generated from stem cells are loaded into thin devices and implanted under the skin. While initial assessments in patients are encouraging, insulin production from the transplanted cells is currently inadequate to reverse diabetes. Our goal is to utilize our broad expertise and a new lab-based model of human islet development to significantly improve upon the manufacturing of the islets to obtain more robust insulin delivery. To achieve this, we have assembled a team of leading experts who will apply their diverse and complementary skills to develop novel strategies to improve the generation of fully functional stem cell derived islets. In particular, we will engineer new cell culture methods to selectively control islet architecture and enhance cell fitness. Collectively our work may form the basis for new clinical trials in patients with type 1 diabetes, and ultimately generate an effective therapy that will free Canadians from insulin injections.
Programme
Team Grant: DM/TS - CIHR-JDRF - ß-cell and Pancreatic Islet Physiology
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
454363
Name
Kieffer Timothy J
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Breakthrough T1D Canada (Ontario)
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Team Grant: Diabetes Mechanisms and Translational Solutions
Projecttitle
Designing Stem Cell Derived Islets for Diabetes Therapy
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$1,000,000
Cihrequipment2
$0
Programname2
Team Grant: DM/TS - CIHR-JDRF - ß-cell and Pancreatic Islet Physiology
Keyworddelim
Biomedical Engineering; Bioprocess Engineering; Cell Transplantation; Diabetes; Islets; Pseudoislets; Stem Cells
Abstract
Diabetes is a debilitating disorder of high blood sugar that afflicts millions of Canadians. People living with type 1 diabetes lack the cells that release the hormone insulin, so multiple daily insulin injections remain the conventional way to control blood sugar levels and survive. Scientists in Edmonton made breakthroughs for the transplant of clusters of insulin-producing cells, called islets. The "Edmonton Protocol" is quick and works remarkably well, such that many islet recipients are able to reduce or even eliminate insulin injections. Unfortunately, the only source of islets for transplant is recently deceased donors and only a tiny fraction of those in need can receive them. There have been remarkable breakthroughs in unraveling the process by which islet cells develop naturally in the body. As a result, it is now possible to replicate this process in the lab with cultured stem cells, culminating in insulin producing cells. Exciting clinical trials are now underway in which islet precursor cells generated from stem cells are loaded into thin devices and implanted under the skin. While initial assessments in patients are encouraging, insulin production from the transplanted cells is currently inadequate to reverse diabetes. Our goal is to utilize our broad expertise and a new lab-based model of human islet development to significantly improve upon the manufacturing of the islets to obtain more robust insulin delivery. To achieve this, we have assembled a team of leading experts who will apply their diverse and complementary skills to develop novel strategies to improve the generation of fully functional stem cell derived islets. In particular, we will engineer new cell culture methods to selectively control islet architecture and enhance cell fitness. Collectively our work may form the basis for new clinical trials in patients with type 1 diabetes, and ultimately generate an effective therapy that will free Canadians from insulin injections.
Competitiondate
202107
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Kieffer, Timothy J; Hoesli, Corinne; Rideout, Elizabeth J; Shakiba, Nika
Approvedterm
5 ans 0 mois
Cihrcontribution2
Inst of Infection & Immunity~ $500,000~ $0~Inst of Nutr Metabolism &Diab~ $500,000~ $0~